BBI Brickell Biotech, Inc.

Brickell Biotech, Inc. engages in the development of prescription therapeutics for treatment of skin diseases. Its product pipeline includes potential novel therapeutics for hyperhidrosis, cutaneous T-cell lymphoma, psoriasis, and other prevalent severe skin diseases. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.

As of 11/26/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/31/1999
Outstanding shares:  115,048,346
Average volume:  3,115,073
Market cap:   $37,655,324
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    10802T105
ISIN:        US10802T1051
Valuation   (See tab for details)
PE ratio:   -0.90
PB ratio:   1.41
PS ratio:   115.15
Return on equity:   -204.19%
Net income %:   -12,468.50%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy